These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1627787)

  • 1. Interleukin-6 in autoimmune disorders.
    Yoshizaki K; Kuritani T; Kishimoto T
    Semin Immunol; 1992 Jun; 4(3):155-66. PubMed ID: 1627787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogene expression in autoimmune mice.
    Mountz JD; Mushinski JF; Mark GE; Steinberg AD
    J Mol Cell Immunol; 1985; 2(3):121-31. PubMed ID: 3916923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The evidence for interleukin-6 as an autocrine growth factor in malignancy.
    Akira S; Kishimoto T
    Semin Cancer Biol; 1992 Feb; 3(1):17-26. PubMed ID: 1643291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoreactivity accelerates the development of autoimmunity and lymphoproliferation in MRL/Mp-lpr/lpr mice.
    Weston KM; Yeh ET; Sy MS
    J Immunol; 1987 Aug; 139(3):734-42. PubMed ID: 3110283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL6 and lymphoproliferative disorders.
    Brouet JC; Levy Y
    Nouv Rev Fr Hematol (1978); 1991; 33(6):433-6. PubMed ID: 1818294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The B cell is the initiating antigen-presenting cell in peripheral lymph nodes.
    Janeway CA; Ron J; Katz ME
    J Immunol; 1987 Feb; 138(4):1051-5. PubMed ID: 3100626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-2, a pro-autoimmune lymphokine that interferes with post-deletional tolerance.
    Kroemer G; Martínez C
    Semin Immunol; 1992 Jun; 4(3):167-79. PubMed ID: 1627788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular basis of elevated c-myb expression in the abnormal L3T4-, Lyt-2- T lymphocytes of autoimmune mice.
    Evans JL; Boyle WJ; Ting JP
    J Immunol; 1987 Nov; 139(10):3497-505. PubMed ID: 3316384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with high doses of anti-IgM prevents, but with lower doses accelerates autoimmune disease in (NZW x BXSB)F1 hybrid mice.
    Cerny A; Starobinski M; Hügin AW; Sutter S; Zinkernagel RM; Izui S
    J Immunol; 1987 Jun; 138(12):4222-8. PubMed ID: 3495583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo cytokine gene expression in various T cell subsets of the autoimmune MRL/Mp-lpr/lpr mouse.
    Mori K; Kobayashi S; Inobe M; Jia WY; Tamakoshi M; Miyazaki T; Uede T
    Autoimmunity; 1994; 17(1):49-57. PubMed ID: 7517710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of B cell abnormalities in the systemic autoimmune syndromes of lpr and gld mice.
    Eisenberg RA; Sobel ES; Reap EA; Halpern MD; Cohen PL
    Semin Immunol; 1994 Feb; 6(1):49-54. PubMed ID: 8167307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The "new" interleukins.
    Romagnani S
    Allergol Immunopathol (Madr); 1991; 19(3):136-42. PubMed ID: 1799172
    [No Abstract]   [Full Text] [Related]  

  • 13. In vivo models for studying the role of autocrine or paracrine growth factors in hematologic malignancies.
    Soma T; Dunbar CE
    Exp Hematol; 1995 May; 23(5):385-8. PubMed ID: 7720810
    [No Abstract]   [Full Text] [Related]  

  • 14. Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome.
    Choi Y; Ramnath VR; Eaton AS; Chen A; Simon-Stoos KL; Kleiner DE; Erikson J; Puck JM
    Clin Immunol; 1999 Oct; 93(1):34-45. PubMed ID: 10497009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acceleration of lpr lymphoproliferative and autoimmune disease by transgenic protein kinase CK2 alpha.
    Rifkin IR; Channavajhala PL; Kiefer HL; Carmack AJ; Landesman-Bollag E; Beaudette BC; Jersky B; Salant DJ; Ju ST; Marshak-Rothstein A; Seldin DC
    J Immunol; 1998 Nov; 161(10):5164-70. PubMed ID: 9820486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model.
    Nagata S
    J Hum Genet; 1998; 43(1):2-8. PubMed ID: 9609991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavior and immune status of MRL mice in the postweaning period.
    Sakić B; Szechtman H; Talangbayan H; Denburg S; Carbotte R; Denburg JA
    Brain Behav Immun; 1994 Mar; 8(1):1-13. PubMed ID: 8003767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo depletion of Thy-1-positive cells originating from normal bone marrow abrogates the suppression of gld disease in normal-gld mixed bone marrow chimeras.
    MacDonald GC; Kakkanaiah VN; Sobel ES; Cohen PL; Eisenberg RA
    J Immunol; 1995 Jan; 154(1):444-9. PubMed ID: 7527820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis.
    Horii Y; Iwano M; Hirata E; Shiiki M; Fujii Y; Dohi K; Ishikawa H
    Kidney Int Suppl; 1993 Jan; 39():S71-5. PubMed ID: 8468929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective elimination of non-lpr lymphoid cells in mice undergoing lpr-mediated graft-vs-host disease.
    Perkins DL; Michaelson J; Glaser RM; Marshak-Rothstein A
    J Immunol; 1987 Sep; 139(5):1406-13. PubMed ID: 2887617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.